Leonard Rappaport, MD
Ophthalmology · Portsmouth, VANPI 1659381408
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (44.2%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Aerie Pharmaceuticals, Inc. accounts for 77.9% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2019 at $27,011 and has fallen 94.6% since, to $1,458 in 2025. Among ophthalmology clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 265 payments — averaging $321.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aerie Pharmaceuticals, Inc.$66K
- Alcon$14K
- AbbVie$2K
- NEW World Medical,inc.$474
- Bausch & Lomb Americas Inc.$461
- Bausch & Lomb, A Division Of Bausch Health US, LLC$397
- plus $2K from 18 others
What the payments were for
- Consulting fees$30,19935%
- Speaking & faculty fees$37,59244%
- Travel & lodging$7,9659%
- Food & beverage$9,34211%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Aerie Pharmaceuticals, Inc. | 83 | $66,289 |
| Alcon | 45 | $13,516 |
| AbbVie(2 entities) | 68 | $2,133 |
| NEW World Medical,inc. | 5 | $474 |
| Bausch & Lomb Americas Inc. | 12 | $461 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 12 | $397 |
| Sight Sciences, Inc. | 8 | $376 |
| Ivantis, Inc | 3 | $339 |
| Glaukos Corporation | 2 | $337 |
| Mallinckrodt Hospital Products Inc. | 2 | $144 |
| Sun Pharmaceutical Industries Inc. | 6 | $132 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $117 |
| Shire North American Group Inc | 4 | $64 |
| Thea Pharma Inc. | 2 | $45 |
| Tarsus Pharmaceuticals, Inc. | 2 | $43 |
| Novartis | 1 | $40 |
| Oasis Medical, Inc. | 1 | $39 |
| Rayner Intraocular Lenses Limited | 1 | $38 |
| Dompe US, Inc. | 1 | $23 |
| Harrow Eye, LLC | 1 | $22 |
| Mallinckrodt Enterprises LLC | 1 | $21 |
| Kala Pharmaceuticals, Inc. | 1 | $16 |
| Oyster Point Pharma, Inc. | 1 | $15 |
| Eyevance Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rocklatan$76,670
- Rhopressa$71,487
- Clareon$819
- LUMIGAN$457
- Hydrus$273
- iDose$232
- Kahook Dual Blade$208
- Streamline Surgical System$208
- Ahmed Glaucoma Valve$208
- Hydrus Microstent$184
- Clareon PanOptix Pro$144
- VYZULTA$137
- XEN GLAUCOMA TREATMENT SYSTEM$124
- DURYSTA$120
- PanOptix$118
- COMBIGAN$117
- ARGOS$110
- XEN$109
- ACTHAR$106
- RADIUS$104
How this compares
$85,097 in reported general payments places this provider in the 95th percentile of 509 ophthalmology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 592 | $323,961 |
| RhopressaNetarsudil Mesylate | 327 | $181,680 |
| CombiganBrimonidine Tartrate/Timolol | 271 | $108,158 |
| RocklatanNetarsudil Mesylat/Latanoprost | 189 | $97,657 |
| VyzultaLatanoprostene Bunod | 199 | $89,370 |
| Alphagan PBrimonidine Tartrate | 175 | $70,708 |
| Brimonidine Tartrate | 727 | $68,578 |
| RestasisCyclosporine | 48 | $68,484 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 346 | $57,994 |
| Lotemax SmLoteprednol Etabonate | 128 | $33,343 |
| Brinzolamide | 166 | $30,343 |
| Prednisolone Acetate | 650 | $27,255 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 89 | $25,484 |
| XiidraLifitegrast | 15 | $18,597 |
| Cyclosporine | 15 | $11,359 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Alphagan P, Restasis | $2,133 | $571,3111,086 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $66,289 | $279,336516 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra | $461 | $107,967214 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Loteprednol Etabonate | $397 | $36,668145 claims |
| AlconSimbrinza, Azopt | $13,516 | $32,317104 claims |
| Thea Pharma Inc.Iyuzeh | $45 | $6,55512 claims |
| NovartisIlevro | $40 | $4,45312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 509 ophthalmology providers in Virginia.
Other ophthalmology in Portsmouth
- Ethnie JonesRichmond$2M
- Elizabeth Yeu-LinNorfolk$1.7M
- John SheppardNorfolk$1.1M
- Constance OkekeNorfolk$800K
- Marc OdrichCharlottesville$497K
- Jayakrishna AmbatiCharlottesville$116K
- Thomas JolyNorfolk$95K
- Stephen ScoperNorfolk$88K
- Soheila RostamiReston$73K
- James PaauwLynchburg$71K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.